Fattori condizionanti la sopravvivenza nel paziente con scompenso di cuore

Similar documents
SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA

Online Appendix (JACC )

Heart Failure Update John Coyle, M.D.

Heart Failure (HF) Treatment

Heart Failure Clinician Guide JANUARY 2018

HFpEF. April 26, 2018

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

The ACC Heart Failure Guidelines

Heart Failure Clinician Guide JANUARY 2016

Topic Page: congestive heart failure

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Heart.org/HFGuidelinesToolkit

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Therapeutic Targets and Interventions

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Diastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

The Failing Heart in Primary Care

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Diastolic Heart Failure Uri Elkayam, MD

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta

Congestive Heart Failure: Outpatient Management

The CCS Heart Failure Companion: Bridging Guidelines to your Practice

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

Summary/Key Points Introduction

HFpEF, Mito or Realidad?

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

I have no disclosures. Disclosures

Heart failure hospitalizations with preserved or reduced ejection fraction

Heart. Severe. Failure. Congestive heart failure (CHF) is very. What you can do for your patients

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

WHAT S NEW IN HEART FAILURE

ARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists

Chapter 4 Section 9.1

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Heart Failure: Guideline-Directed Management and Therapy

2016 Update to Heart Failure Clinical Practice Guidelines

How to Evaluate the Heart of Elderly Patients

LXIV: DRUGS: 4. RAS BLOCKADE

Chapter 4 Section 9.1

Objectives. Outline 4/3/2014

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Metoprolol CR/XL in Female Patients With Heart Failure

Chapter 4: Cardiovascular Disease in Patients with CKD

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Quality Payment Program: Cardiology Specialty Measure Set

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

Hemodynamic Monitoring

*NOTE: When reporting C P T code and 99239, it is recommended the measure be reported each time the code is submitted for hospital discharge.

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

Heart Failure Background, recognition, diagnosis and management

Heart Failure A Team Approach Background, recognition, diagnosis and management

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

Innovation therapy in Heart Failure

Recently, much effort has been put into research. Advances in... Congestive Heart Failure Care. How is CHF diagnosed? 2.

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Managing HTN in the Elderly: How Low to Go

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

Definition of Congestive Heart Failure

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

Module 1: Evidence-based Education for Health Care Professionals

Therapeutic Targets and Interventions. Ali Valika, MD, FACC Advocate Medical Group

A patient with decompensated HF

Long-Term Care Updates

Heart Failure A Disease for the Internist?

Heart Failure with preserved ejection fraction (HFpEF)

Supplementary Online Content

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL

Long-Term Care Updates

Updates in Congestive Heart Failure

Management Strategies for Advanced Heart Failure

Heart Failure Guidelines For your Daily Practice

HEART FAILURE QUALITY IMPROVEMENT. American Heart Association Shawni Smith Regional Director, Quality & Systems Improvement

AF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management

Peripartum Cardiomyopathy. Lavanya Rai Manipal

Evidence Supporting Post-MI Use of

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

Lnformation Coverage Guidance

Χριστίνα Χρυσοχόου Καρδιολόγος Επι,Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών, ΙΓΝΑ

HFNEF. Heart Failure is

Chapter 4 Section 9.1

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Transcription:

Journal Club 13 Febbraio 2008 Fattori condizionanti la sopravvivenza nel paziente con scompenso di cuore Intissar Sleiman

Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007

Incidence of heart failure by age and sex (FHS 1980-2003) Circulation, 2007

Peculiarità del paziente anziano - Di malattia - Di terapia - Di prognosi

Peculiarità del paziente anziano Di malattia -Di terapia - Di prognosi

NEJM, 1985

JACC, 2006

JACC, 2006

JACC, 2006

NEJM, 2006

NEJM, 2006

Diastolic Heart Failure or FH with normal ejection fraction More likely to be older, female, and hypertensive Less likely to have had a prior myocardial infarction or to be receiving an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker. Lower in-hospital mortality but similar ICU and hospital length of stay.

Peculiarità del paziente anziano - Di malattia Di terapia - Di prognosi

Treatment for patients with heart failure and preserved ejection fraction Control of systolic and diastolic hypertension Control of ventricular rate in patients with atrial fibrillation Control of pulmonary congestion and peripheral edema with diuretics Coronary revascularization in patients with CHD in whom ischemia is judged to have an adverse effect on diastolic function

Drugs Aging, 2007

Drugs Aging, 2007

Drugs Aging, 2007

Drug treatment of chronic heart failure in elderly patients is, in principle, identical to that in younger patients. However, drug treatment in elderly patients requires more careful monitoring, adjustments to therapy..given the low use of recommended drugs in elderly patients, multidisciplinary approaches may be particularly useful in this regard. Drugs Aging, 2007

JAMDA, 2008

D Diagnosis Make a clinical diagnosis of heart failure before ordering any test, especially an echocardiogram. A normal ejection fraction in a patient without a clinical diagnosis may confound the diagnosis process. If a clinical diagnosis is already made or patient had hospitalization due to heart failure, check how the diagnosis was established. E Etiology Hypertension and myocardial infarction are the two most common causes. Expect multiple causes in elderly heart failure patients in the long-term care setting. Continued treatment of risk factors such as high blood pressure and myocardial ischemia is important to prevent disease progression. F Fluid volume Single most important physical examination. Best assessed by estimating jugular venous pressure in the neck. External jugular veins are very useful if their limitations are appreciated. Being superficial veins they are subject to external pressure or internal obstruction. Thus a distended external jugular vein without visible pulsation should not generally be used to estimate venous pressure. EA Ejection fraction Single most important test after a clinical diagnosis of heart failure has been made. It is a marker of prognosis (generally patients with lower ejection fraction have a poorer prognosis) and a guide to therapy. T Treatment Heart failure therapy can be divided into symptom-relieving and life-prolonging therapies. The two most important life-prolonging therapies for heart failure patients with low ejection fraction (45%) are ACE inhibitors (or an ARB if intolerant to ACE inhibitor) and beta-blockers (those approved for use in heart failure and shown to reduce mortality, namely metoprolol extended release and carvedilol). Survival benefit of these drugs in diastolic heart failure has not yet been proven. All symptomatic heart failure patients with fluid volume overload should be treated with a diuretic and once euvolemia is achieved the lowest possible dose should be used to maintain euvolemia in conjunction with salt and fluid restriction. Digitalis in low doses (0.125 mg or less per day) should be used to reduce symptoms and risk of hospitalization. In patients who cannot tolerate beta-blockers at low dosages, digitalis can also reduce mortality. JAMDA, 2008

HF in the long-term care setting is a complex syndrome, the management of which can be challenging...guidelines provide little specific information for HF patients in the long-term care setting. However, familiarity with a major national guideline may provide a foundation on which HF treatment in the long-term care setting can be individualized. JAMDA, 2008

The seattle Heart failure model Circulation 2006

Peculiarità del paziente anziano Di malattia - Di terapia Di prognosi

Arch Intern Med 2006

Arch Intern Med 2006

Circ Heart Fail, 2008

Depression and Major Outcomes in Older Patients With Heart Failure Arch Intern Med, 2002

Short-Term Survival in Elderly Patients Hospitalized for Heart Failure: the Role of Diabetes and newly Recognized Hyperglycemia. JAGS, 2009 In press

JAGS, 2009 In press

JAMA 2009

In conclusion, the time course of heart failure therapy is gradual, composed of up titration of medications, reassessment of patient symptoms and signs, clinician persistence and patience, and obtaining BNP levels. There are no easy answers and no simple solutions in the search for a single biomarker for diagnosis, prognosis, and treatment of heart failure. JAMA, 2009